ArticleBioMed research international2026
Serum Interleukin-35 Levels in Oral Squamous Cell Carcinoma and Salivary Gland Tumors: Implications for Early Detection and Prognosis.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Interleukin-35 Levels in Oral Squamous Cell Carcinoma and Salivary Gland Tumors: Implications for Early Detection and Prognosis.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral cancer, particularly oral squamous cell carcinoma (OSCC), is a major global health concern, with late-stage diagnoses significantly lowering survival rates. Salivary gland tumors (SGTs), though less common, pose diagnostic challenges due to their varied presentation. This study investigates the role of interleukin-35 (IL-35) in OSCC and SGTs, aimed at assessing its potential as a biomarker for early detection and prognosis. Methods: A cross-sectional study was conducted, including 65 OSCC patients, 65 SGTs patients, and 50 healthy individuals as a control group. Inclusion criteria included age over 18 years, negative HPV confirmation, and histopathologically confirmed cancer diagnosis (SGT or OSCC). Blood samples were collected from all participants. Serum IL-35 levels were measured using the ELISA kit. Results: IL-35 levels varied significantly between the groups ( Conclusions: The study indicates that IL-35 levels are notably reduced in SGTs compared to healthy individuals. However, no significant difference was observed between benign and malignant SGTs. The absence of significant correlation in OSCC patients suggests that IL-35 may have a minor role in this type of cancer, highlighting the potential need for other biomarkers to improve early detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.